242results about How to "Increase oxygenation" patented technology

Utilization of a contact device placed on the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the conjunctiva and in the tear film. A transensor mounted in the contact device laying on the cornea or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system utilizes eye lid motion and / or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by wires or radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like.

A system and method for ventilating a lung in a living being by varying the peak inspiratory pressure. The peak inspiratory pressure may deviate about a mean that is chosen to correspond with a knee in a pressure-volume curve of the lung.

Disclosed are methods and compositions for increasing tissue oxygen levels by administration of superoxygenated compositions of tissue surfaces. The methods are applicable to treatment of a wide variety of conditions including burns, bedsores, ulcers, necrosis and anaerobic infections.

The present invention restores the normal low-dose flushing of the lower airways with air from the upper airways, containing nitric oxide (NO) and possible other biologically active agents by aspiration of air from the upper airways and introducing said air in the inspiratory airflow of a ventilator. The inventive apparatus and method is free from the risks associated with traditional administration of exogenous NO.

A nasal dilator includes a contact pad attachable to a user's facial region below the user's eye and outboard from the user's nose. A tugging device is coupled with the contact pad and urges the contact pad in a direction away from the user's nose. With this structure, effective dilation of the nasal passages can be achieved in a comfortable manner. The dilator may also be incorporated into a CPAP mask and / or form part of an automated control system.

Disclosed are methods and compositions for increasing tissue oxygen levels by administration of superoxygenated compositions of tissue surfaces. The methods are applicable to treatment of a wide variety of conditions including burns, bedsores, ulcers, necrosis and anaerobic infections.

In one aspect, the present invention is directed to an apparatus and method for treating congestive heart failure that restores kidney renal functions by artificial perfusion of at least one kidney. In one aspect, a catheter inserted into the aorta of the patient has an outlet port that supplies the patient's blood obtained from a patient's aorta into an adjoining renal artery of the patient to perfuse the kidney. The catheter comprises a rotor housed inside a portion of the catheter to supply the blood to the kidney at a desired pressure. The restoration of kidney function assists the heart by removing excess fluid, urine and toxin from the patient, and by normalizing the patient's renin-angiotensin system and other neurohormonal substances.

A nasal dilator includes a contact pad attachable to a user's facial region below the user's eye and outboard from the user's nose. A tugging device is coupled with the contact pad and urges the contact pad in a direction away from the user's nose. With this structure, effective dilation of the nasal passages can be achieved in a comfortable manner. The dilator may also be incorporated into a CPAP mask and / or form part of an automated control system.

An aeroponic growing system, double T-shaped sprayer design and method for cultivating larger plant crops and increasing harvest frequency. The system comprises a series of aeroponic growing units, each of which supports a plant's roots within an enclosure. The enclosure houses a sprayer, an interior volume of plant nutrient solution and a plumbing system for accepting and distributing the aqueous water-nutrient solution. The internal sprayer is a double T-shaped mister that sprays an atomized mist directed from a first set of nozzles onto the plant roots, along with a second set of nozzles directed toward the base of the enclosure to aerate the interior volume of plant nutrient solution. The T-shaped mister provides circumferential coverage of the plant roots, while the aeration of the plant nutrient solution provides an aerated solution that accelerates plant growth through a hybrid process of Nutrient Film Technique (NFT) called a Hyperactive Aeroponic Shallow Water Culture (HAS Culture). Several interconnected aeroponic growing units may be stationed in a parallel grid to provide ample space for rapid growth of crops, while supplying the water and nutrient solution through a network of pipes and tubes between units.

The present invention is drawn to a unique apparatus and method for treating and reusing the wastewater discharged from agricultural animal farms. The apparatus and method of the present invention may be readily sized and configured depending upon the amount and constituent(s) of the wastewater to be treated. In a first embodiment, the apparatus and method of the present invention is designed to be a zero discharge system in which no wastewater will be discharged or spray irrigated. In use, the apparatus and method of the first embodiment may actually require addition of make-up water during periods of low rainfall to make-up water losses due to evaporation and drift. It is contemplated that the only byproduct of the apparatus and method of the first embodiment may be a beneficial sludge if a sufficient number of installations are operated. In a second embodiment, the apparatus and method of the present invention provides a treatment system capable of reducing the nutrient loading in a step-wise fashion so that the wastewater can be used from different steps of treatment in order to apply the varying nutrient loads required by crops on a seasonal basis.

A system and method of sustainable aquaponics that vertically integrates unique aquaponic system designs with alternative aquaculture fish feed sources, fingerling production methods, alternative aquaculture / farmed fish grow out models, and green energy sources that yield organic produce in the form of fruits and vegetables. A raceway system serves for grow-out throughout the warm and cold months. During the summer months, fish can be spawned and fed for steady growth, while during the winter months, the fish continue to grow at slower quite acceptable growth rates. The present invention derives its water from an open, natural, established pond or lake ecosystem to ensure that the raceways are adequately seeded with all of nature's good and bad bacteria and algae. The present invention can include winter quarters for the fish that is well-insulated and heated to ensure that the fish are comfortable and will continue growing and spawning throughout winter months.

Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.

Lung conditions are treated by implanting a flow restrictor in a passageway upstream from a diseased lung segment. The restrictor will create an orifice at the implantation site which inhibits air exchange with the segment to induce controlled atelectasis and / or hypoxia. Controlled atelectasis can induce collapse of the diseased segment with a reduced risk of pneumothorax. Hypoxia can promote gas exchange with non-isolated, healthy regions of the lung even in the absence of lung collapse.

A multilumen unilimb breathing circuit with a detachable proximal fitting for providing respiratory gases to and receiving expiratory gases from a patient. The circuit has unique fittings for connection to patient devices or assisted ventilation systems and components. Despite many teachings away in the prior art from making breathing circuit tubing detachable from the proximal terminal, the proximal end of the rigid multilumen proximal fitting can be attached and detached by a user at a site of use to a mating multilumen proximal terminal while its distal end can be attached to multiple lumens formed of flexible tubing for carrying gases to and from a patient. The present invention introduces for the first time to the multilumen unilimb circuit art a detachable proximal fitting.

A process for operating a respirator and / or anesthesia device in the APRV mode with the % PEF criterion which includes a detection of a spontaneous expiratory effort by the patient and initiation of a pressure release phase when the detected spontaneous expiratory effort by the patient falls within a predetermined trigger window (Tfreg). A device is provided that is operated correspondingly.

Treatment of pulmonary disorders associated with hypoxemia and / or smooth muscle constriction and / or inflammation comprises administering into the lungs as a gas compound with an NO group which does not form NO2 / NOx in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure, hypertension, sickle cell disease and clotting disorders, comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and / or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO2 / NOx in the presence of oxygen or reactive oxygen species at body temperature. Exemplary of the compound administered in each case is ethyl nitrite.

Inhalant anesthetics are developed with a number of properties including rapid onset and recovery, controllability, and, ideally, a broad safety profile. The efficacy of these agents is measured by their ability to create anesthesia within the framework of the other desirable properties. The instant invention focuses on the dosage level where analgesia occurs but amnesia or lack of consciousness does not. In addition to identifying the dosage level where pain is sharply reduced or eliminated but awareness remains, a delivery system for safe and effective delivery of the agent is described.

Provided herein are compositions and methods for preventing, ameliorating, and / or reducing tissue ischemia and / or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and / or blocking TSP1 and / or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death. The therapeutics identified herein allow for precise regulation of blood flow to tissues and organs which need it, while substantially avoiding systemic complications. Methods and compositions described herein can be used to increase tissue survival under conditions of trauma and surgery, as well as conditions of chronic vascular disease. Also disclosed are methods for the treatment of elderly subjects using agents that affect TSP1 and CD47 and thereby affect tissue perfusion. Additionally, provided herein are compositions and methods for influencing blood coagulation, allowing for controlled increased or decreased blood clotting. Additionally, provided herein are compositions and methods for decreasing blood flow, as in the case of cancer through mimicking the effects of TSP1 and CD47 on blood vessel diameter and blood flow.

The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.

Disclosed are methods of subcutaneous delivery of a drug or a therapeutic agent to a subject comprising administering to said subject a tumescent composition comprising: (a) the drug or the therapeutic agent, wherein a tumescent concentration of the drug is simultaneously: 1) below a threshold for local, subcutaneous tissue toxicity, 2) above a threshold for positive local therapeutic effect, and 3) above a concentration achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery; (b) a vasoconstrictor; and (c) a pharmaceutically acceptable carrier. Some embodiments relate to a method of treating or preventing sepsis or Systemic Inflammatory Response Syndrome (SIRS) in a subject. Some embodiments relate to a tumescent solution for treating a localized viral infection, e.g., varicella-zoster (shingles), the tumescent solution comprising an antiviral agent.

Provided herein are compositions and methods for preventing, ameliorating, and / or reducing tissue ischemia and / or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and / or blocking TSP1 and / or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death. The therapeutics identified herein allow for precise regulation of blood flow to tissues and organs which need it, while substantially avoiding systemic complications. Methods and compositions described herein can be used to increase tissue survival under conditions of trauma and surgery, as well as conditions of chronic vascular disease. Also disclosed are methods for the treatment of elderly subjects using agents that affect TSP1 and CD47 and thereby affect tissue perfusion. Additionally, provided herein are compositions and methods for influencing blood coagulation, allowing for controlled increased or decreased blood clotting. Additionally, provided herein are compositions and methods for decreasing blood flow, as in the case of cancer through mimicking the effects of TSP1 and CD47 on blood vessel diameter and blood flow.

The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.

The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.

The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphospahte (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.

Methods and apparatus for administering CPAP to a patient are disclosed. The method includes providing a controllable flow of gas from a source to a patient creating a continuous positive airway pressure and controlling the flow of gas so that it is periodically modified to inject a sigh cycle into the CPAP. The administration of sigh cycle inclusive CPAP is useful for the treatment of respiratory dysfunction and for stimulating the release of surfactant in immature lungs. It is preferred to monitor the airway pressure and to inject the sigh cycle when a drop in pressure is detected. The apparatus centers on a driver used in conjunction with a gas delivery. The driver includes a valve, adapted to receive gas from a source, for regulating the flow of gas to the delivery device in response to a control signal. A controller, connected to the valve, generates the control signal so that the valve periodically modifies the flow of gas, thereby injecting a sigh cycle. A sensor is connected to sense the airway pressure and generate a pressure signal representative of the airway pressure. The controller periodically modifies the flow of gas in response to this pressure signal. It is especially preferred to initiate a sigh cycle when a drop in airway pressure is sensed.